A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML

Inclusion Criteria

• •1. Male or female patient ≥ 18 years
• •2. Philadelphia chromosome positive newly diagnosed chronic myelogenous leukaemia (≤ 4 months) in first chronic phase.
• •3. Not previously treated with tyrosine kinase inhibitors other than imatinib
• •4. Prior treatment with imatinib during less than 13 weeks
• •5. Signed written inform consent
• •6. Women of childbearing potential (WOCBP) must be using an adequate method of contraception